<DOC>
	<DOC>NCT00750087</DOC>
	<brief_summary>the primary purpose of the study is to observe symptoms control in schizophrenia for 6 months in patients treated with Seroquel XR. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Non-interventional Study -Observe Treatment Efficacy in Maintaining Symptoms Control in Schizophrenia With Seroquel XR</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patients will have a diagnosis of schizophrenia , as defined by DSMIVTR and their symptoms are controlled with Seroquel XR therapy started approximately 1 month before All eligible patients will be included in the protocol provided they will receive detailed information in advance and will sign consent to grant access to their own data collected during this programme. All the patients who have a known hypersensitivity to Seroquel XR/quetiapine or any of its excipients will not be included in this study. As per valid Romanian SmPC, concomitant medication, that could result in drug interactions and could jeopardise patient safety will be carefully considered before having the patient enrolled.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>